<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Public Citizen</provider_name><provider_url>https://www.citizen.org</provider_url><author_name>Diane Krauthamer</author_name><author_url>https://www.citizen.org/author/dkrauthamer/</author_url><title>Comments to the FDA Supporting Draft Guidance Restricting Orphan Drug Designations for Pediatric Uses - Public Citizen</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="fSdQ6FHwbF"&gt;&lt;a href="https://www.citizen.org/article/comments-to-the-fda-supporting-draft-guidance-restricting-orphan-drug-designations-for-pediatric-uses/"&gt;Comments to the FDA Supporting Draft Guidance Restricting Orphan Drug Designations for Pediatric Uses&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.citizen.org/article/comments-to-the-fda-supporting-draft-guidance-restricting-orphan-drug-designations-for-pediatric-uses/embed/#?secret=fSdQ6FHwbF" width="600" height="338" title="&#x201C;Comments to the FDA Supporting Draft Guidance Restricting Orphan Drug Designations for Pediatric Uses&#x201D; &#x2014; Public Citizen" data-secret="fSdQ6FHwbF" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>Public Citizen filed comments supporting a Food and Drug Administration (FDA) draft guidance, in which the FDA declared that it would no longer grant orphan drug designation to drugs for use in pediatric subpopulations of common diseases or conditions unless: 1) The disease in the pediatric population constitutes a valid orphan subset, or 2) the disease in the pediatric subpopulation is a different disease from the disease in the adult population.</description><thumbnail_url>https://www.citizen.org/wp-content/uploads/public_citizen_shared_link.jpg</thumbnail_url><thumbnail_width>1200</thumbnail_width><thumbnail_height>628</thumbnail_height></oembed>
